...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4
【24h】

Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4

机译：丙型肝炎病毒4型异质性患者γ-干扰素诱导蛋白10 kDa与病毒应答的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: The role of serum interferon-γ-inducible protein-10 kDa (IP-10) level in the treatment of chronic hepatitis C genotype-4 (HCV-4) and its various subtypes remains unknown. We aimed to study the impact of pretreatment IP-10 levels on the sustained viral response (SVR) in HCV-4 patients (n=64) undergoing peginterferon α-2a/ribavirin therapy. PATIENTS AND METHODS: Pretreatment IP-10 levels and HCV-4 subtypes (4a=48.4%, 4d=39%, others=12.5%) were measured and correlated with treatment responses. Variables significantly associated with SVR on univariate analysis were included in a multivariate logistic regression model. RESULTS: Patients with SVR had lower pretreatment IP-10 levels (462.4±282.7 vs. 840.1±490.6 pg/ml; P=0.002), but the levels were not significantly different in those with a rapid (P=0.245) or an early viral response (P=0.221). IP-10 levels were similar across all subtypes. The pretreatment level was significantly lower in subtype 4d patients with SVR (465.9±349.1) compared with non-SVR patients (904.9±532.1; P<0.001), but not when compared with genotype 4a patients (564.7±288.9 vs. 658.6±374.9, respectively; P=0.330). IP-10 levels [odds ratio (OR), 0.998; 95% confidence interval (CI): 0.996-0.999; P=0.006], low viremia (OR, 8.852; 95% CI: 1.244-63.03; P=0.029), and early viral response (OR, 4.162; 95% CI: 1.023-16.94; P=0.046) were independent predictors of SVR. Receiver operating characteristic curve analysis identified a threshold IP-10 level of 359 pg/ml (area under receiver operating characteristic curve, 0.737; sensitivity, 81.8%; specificity, 45.2; positive predictive value, 43.9%; negative predictive value, 82.6%) for SVR. CONCLUSION: Pretreatment serum IP-10 level is a predictor for SVR in HCV-4-infected patients. The baseline IP-10 level is significantly lower in responders among HCV genotype-4d patients as compared with 4a patients.
机译：简介：血清干扰素-γ诱导型蛋白10 kDa（IP-10）水平在治疗慢性丙型肝炎基因型4（HCV-4）及其各种亚型中的作用尚不清楚。我们旨在研究预处理IP-10水平对接受聚乙二醇干扰素α-2a/利巴韦林治疗的HCV-4患者（n = 64）的持续病毒应答（SVR）的影响。患者和方法：测量治疗前IP-10水平和HCV-4亚型（4a = 48.4％，4d = 39％，其他= 12.5％）并与治疗反应相关。在单变量分析中与SVR显着相关的变量包括在多变量logistic回归模型中。结果：SVR患者的治疗前IP-10水平较低（462.4±282.7 vs. 840.1±490.6 pg / ml; P = 0.002），但与快速（P = 0.245）或早期的患者相比，水平没有显着差异。病毒反应（P = 0.221）。所有亚型的IP-10水平均相似。与非SVR患者（904.9±532.1; P <0.001）相比，4d亚型SVR患者的治疗前水平显着降低（465.9±349.1），但与基因4a型患者相比（564.7±288.9与658.6±374.9）没有降低，分别为P = 0.330）。 IP-10等级[比值比（OR）为0.998; 95％置信区间（CI）：0.996-0.999; P = 0.006]，低病毒血症（OR，8.852; 95％CI：1.244-63.03; P = 0.029）和早期病毒反应（OR，4.162; 95％CI：1.023-16.94; P = 0.046）是以下因素的独立预测因子SVR。接受者工作特征曲线分析确定IP-10阈值阈值为359 pg / ml（接受者工作特征曲线下的面积为0.737;灵敏度为81.8％;特异性为45.2;阳性预测值为43.9％;阴性预测值为82.6％）用于SVR。结论：预处理血清IP-10水平是HCV-4感染患者SVR的预测指标。在HCV基因型为4d的患者中，应答者的基线IP-10水平显着低于4a患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号